Allogene Therapeutics Inc
Ownership
Ownership Structure
Who owns Allogene Therapeutics Inc (ALLO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 81.6% of the shares are freely tradable; institutional investors hold 53.3%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.73 | 30,146,963 | +57.9 | 06/30/2026 |
| Frazier Life Sciences Management, L.P. | 6.50 | 22,446,668 | +491.2 | 06/30/2026 |
| Pfizer Inc | 6.38 | 22,032,040 | +0.0 | 06/30/2026 |
| State Street Corp | 5.51 | 19,025,826 | +119.7 | 06/30/2026 |
| TPG GP A, LLC | 5.42 | 18,716,306 | +0.0 | 06/30/2026 |
| Sio Capital Management, LLC | 3.86 | 13,323,431 | +0.0 | 06/30/2026 |
| PRIMECAP Management Company | 3.80 | 13,123,440 | +56.6 | 06/30/2026 |
| Vanguard Capital Management, LLC | 3.52 | 12,166,636 | +75.8 | 06/30/2026 |
| FMR Inc | 3.48 | 12,009,043 | +655.4 | 06/30/2026 |
| Citadel Advisors Llc | 2.92 | 10,087,770 | +48.5 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 1,045,877 | 1,150,465 $ | Oct 21, 2026 | direct |
| Douglas Earl Martin | SVP, General Counsel | 488,267 | 537,094 $ | Aug 21, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 21, 2026 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,342 | 1.34 | 48,698 |
| Aug 21, 2026 | Douglas Earl Martin | SVP, General Counsel | Sell | 29,697 | 2.12 | 62,958 |
| Apr 21, 2026 | Annie Yoshiyama | SVP | Sell | 9,586 | 2.31 | 22,144 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.